|
|||||
|
|
| 吉非替尼敏感性预测指标的研究现状 | |
| 引用本文： | 陈玲,陈强,叶韵斌.吉非替尼敏感性预测指标的研究现状[J].中国新药与临床杂志,2006,25(11):864-868. |
| 作者姓名： | 陈玲 陈强 叶韵斌 |
| 作者单位： | 1. 福建医科大学,福建,福州,350004 2. 福建医科大学,福建,福州,350004;福建省肿瘤医院,福建,福州,350014 3. 福建省肿瘤医院,福建,福州,350014 |
| 摘 要： | 吉非替尼是一种表皮生长因子受体酪氨酸激酶(EGFR-TK)抑制剂,其适应证为治疗既往接受过化学治疗(化疗)的局部晚期或转移性非小细胞肺癌(NSCLC)病人。既往的化疗采用铂剂和多西他赛。吉非替尼的临床研究结果表明它对某些NSCLC效果明显,如何选择对该药敏感的病人的研究成为焦点,本文对该方面研究的结果予以综述。 |
| 关 键 词： | 受体 表皮生长因子 癌 非小细胞肺 预测 免疫组织化学 原位杂交 荧光 吉非替尼 |
| 文章编号： | 1007-7669（2006）11-0864-05 |
| 收稿时间： | 2006-04-20 |
| 修稿时间： | 2006-04-202006-09-14 |
Sduties on predictive factors for sensitivity to gefitinib |
|
| CHEN Ling,CHEN Qiang,YE Yun-bin.Sduties on predictive factors for sensitivity to gefitinib[J].Chinese Journal of New Drugs and Clinical Remedies,2006,25(11):864-868. | |
| Authors: | CHEN Ling CHEN Qiang YE Yun-bin |
| Institution: | 1.Fujian Medical University, Fuzhou FUJIAN 350004, China; 2.Fujian Provincial Tumor Hospital, Fuzhou FUJIAN 350014, China |
| Abstract: | Gefitinib is a kind of epidermal growth factor receptor-tyrosine kinase inhibitor. Gefitinib is indicated as the monotherapy for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) after failure of both platinum-based and docetaxel chemotherapies. The results of clinical trials showed that gefitinib was effective especially to some NSCLC patients. The purpose of this review is to focus on how to select patients sensitive to gefitinib. |
| Keywords: | receptor epidermal growth factor carcinoma non-small-cell lung forecasting immunohistochemistry in situ hybridization fluorescence gefitinib |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ | |